Premium
Detection of tumor‐associated antigen in human melanoma cell line supernatants
Author(s) -
Grimm Elizabeth A.,
Silver Hulbert K. B.,
Roth Jack A.,
Chee Darwin O.,
Gupta Rishab K.,
Morton Donald L.
Publication year - 1976
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910170503
Subject(s) - melanoma , complement fixation test , antigen , sarcoma , carcinoma , antibody , cell culture , cancer research , medicine , pathology , immunology , biology , serology , genetics
Spent tissue culture medium (CDM‐S) removed from a single cell line of human malignant melanoma grown in serum‐free CDM, contained tumor‐associated antigenic activity. Antibodies to CDM‐S measured by complement fixation were detected in 44% (31/70) melanoma, 55% (15/27) sarcoma, 63% (24/38) carcinoma and 15% (11/72) normal sera. Delayed cutaneous hypersensitivity reactions (DCHR) were demonstrated in 4/5 melanoma patients at a 500 μg dose, 3/5 at a 100 μg dose and in 1/7 carcinoma patients at the 500 μg dose. One ml of CDM‐S was shown to contain antigen equivalent to that obtained from the membranes of 2.9 × 10 7 tissue‐cultured melanoma cells. After purification, 84% (16/19) sera from melanoma patients, 66% (12/18) from sarcoma and carcinoma patients and 8% (2/26) from normal controls were positive to the antigen by complement fixation.